News

GSK seeks FDA green light for expanded use of RSV vaccine Arexvy
"A regulatory decision by the FDA on this submission is expected in H1 2026. GSK is continuing to seek expanded indications for its RSV vaccine in other geographies including in the European Economic ...
LONDON BRIEFING: DCC sells unit; South32 warns of Mozal impairment
(Alliance News) - DCC announced a deal to sell a part of its technology arm for GBP100 million, GSK is pursuing US approval for expanded use of its RSV jab, while South32 warned of an impairment at an ...
FDA accepts application for GSK's Arexvy, Ashmore assets under management up $1.4bn in Q4
OPEN The FTSE 100 was expected to open 9.7 points lower ahead of the bell on Monday after wrapping up the previous session 0.38% softer at 8,941.12.
US FDA to review GSK bid to extend use of respiratory virus drug
GSK said the US Food and Drug Administration has accepted an application for review to extend the indication of its Arexvy respiratory syncytial virus vaccine to adults aged 18-49 who are at increased ...
GSK seeks FDA nod for expanded use of RSV vaccine in adults
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...
Medical Dialogues23h
Moderna Spikevax gets full USFDA nod for kids 6 months through 11 years at increased COVID risk
Cambridge: Moderna has received approval from the U.S. Food and Drug Administration (FDA) for the supplemental Biologics ...